At present, the global bio-identical hormones replacement market value accounts for USD 36,059.24 Million in 2022. This market is expected to grow with a CAGR of 5.1% for the forecast duration of 2022-2032. The valuation of the bio-identical hormones replacement segment is expected to surpass the value of USD 59,298.50 Million by end of 2032.
Strategies by Bio-Identical Hormones Replacement Therapy Market Player
The players in the global hormone replacement therapy market experience higher competition as the industry is driven by key companies that focus on gaining maximum share and applying market competencies. These players rely on collaborations, strategic partnerships, and acquisitions. Standards of services, and assistance before and post therapies are also decisive factors for industry players to maintain customer trust and edge in markets.
- In October 2018, TherapeuticsMD received FDA approval for its TX-001HR: BIJUVA™ capsules for the treatment of moderate to severe vasomotor symptoms of menopause. According to the company, it is the first and only bio-identical hormone therapy approved by the FDA which uses a combination of estradiol and progesterone.
- The Biostation has recently launched educational eBooks for uncovering root causes and solutions for making customers aware of their health. These guides are designed to give information and treatment solutions leading to customer trust.
Bio-identical Hormones Replacement Therapy Market: Segmentation
The global bio-identical hormones replacement therapy market has been segmented :
- Growth hormone deficiency
By Product Type
- Tablets and capsules
- Creams and gels
- Patches and Implants
By End User
- Research and academics
- North America
- Latin America